title: Effects of oral meloxicam administration to beef cattle receiving lipopolysaccharide administration or vaccination against respiratory pathogens.
abstract: This study evaluated the effects of oral meloxicam administration on metabolic, inflammatory, and acute-phase responses of beef cattle receiving a lipopolysaccharide (LPS) challenge (Exp. 1; d -1 to 6) or vaccinated against respiratory pathogens (Exp. 2; d 7 to 21). Twenty-one Angus steers ( = 11) and heifers ( = 10) were housed in individual pens on d -15 and were offered free-choice water, mineral-vitamin mix, and hay until d 21. In Exp. 1, cattle were ranked on d -1 by sex and BW and assigned to 1) oral meloxicam administration (1 mg/kg BW daily) from day -1 to 6 (MEL8), 2) oral meloxicam administration (1 mg/kg BW) on d 0 and oral lactose monohydrate administration (1 mg/kg BW) on d -1 and from d 1 to 6 (MEL1), or 3) oral lactose monohydrate administration (1 mg/kg BW daily) from d -1 to 6 (CON). On d 0, cattle received an intravenous LPS bolus (0.5 μg/kg BW) concurrently with treatment administration. Rectal temperature (RTEMP) was assessed, and blood samples were collected at -2, 0, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120, and 144 h relative to LPS administration. No treatment effects were detected ( ≥ 0.36) for RTEMP, concentrations of serum tumor necrosis factor α (TNFα), plasma haptoglobin, cortisol, insulin, and leptin, as well as blood mRNA expression of α and cyclooxygenase-2, although all variables increased ( < 0.01) across treatments after LPS administration. In Exp. 2, cattle received the same treatments that they were assigned to in Exp. 1 from d 7 to d 13 and were vaccinated against respiratory pathogens concurrently with treatment administration on d 8. Blood samples were collected, and RTEMP was assessed as in Exp. 1 in addition to 168, 240, and 336 h relative to vaccination. No treatment effects were detected ( ≥ 0.26) for RTEMP, the same plasma and serum variables evaluated in Exp. 1, and serum concentrations of antibodies against or serum titers against bovine respiratory syncytial virus, bovine herpesvirus-1, bovine viral diarrhea virus-1, and parainfluenza-3 virus. All variables increased ( < 0.01) across treatments after vaccination, except for serum TNFα and titers against bovine viral diarrhea virus-1 ( ≥ 0.40). Collectively, this study found no evidence that oral meloxicam administration, at the doses and intervals utilized herein, mitigated the metabolic, inflammatory, and acute-phase reactions elicited by LPS administration or vaccination against respiratory pathogens.
authors.forename: M C
authors.initials: MC
authors.lastname: Rodrigues
authors.forename: R F
authors.initials: RF
authors.lastname: Cooke
authors.forename: R S
authors.initials: RS
authors.lastname: Marques
authors.forename: S A
authors.initials: SA
authors.lastname: Arispe
authors.forename: D H
authors.initials: DH
authors.lastname: Keisler
authors.forename: D W
authors.initials: DW
authors.lastname: Bohnert
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control; D005260:Female; D006242:Haptoglobins / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male; D000077239:Meloxicam; D008903:Minerals; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D014611:Vaccination / Q000662:veterinary; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006242:Haptoglobins; D008070:Lipopolysaccharides; D008903:Minerals; D013843:Thiazines; D013844:Thiazoles; D014765:Viral Vaccines; D000077239:Meloxicam